Illustration of BRL-101 gene therapy for transfusion-dependent β-thalassemia, showing stem cell collection, CRISPR-Cas9 editing of BCL11A, fetal hemoglobin reactivation and restoration of healthy red blood cells.

BRL Medicine’s BRL-101 Meets Primary Endpoint in Pivotal Trial for Transfusion-Dependent β-Thalassemia

August 25, 2026 7 Min Read

BRL Medicine’s gene-edited stem cell therapy BRL-101 has met the prespecified primary efficacy endpoint in a pivotal Chinese study for transfusion-dependent β-thalassemia, with all 30 treated patients achieving transfusion independence and the earliest-treated children now maintaining the benefit for six years.

SHANGHAI, August 25, 2026 — Chinese gene and cell therapy developer BRL Medicine (邦耀生物) has announced a major clinical milestone for BRL-101, its CRISPR-edited autologous hematopoietic stem cell therapy for transfusion-dependent β-thalassemia (TDT).

The pivotal clinical study has met its prespecified primary efficacy endpoint based on the proportion of patients achieving transfusion independence for at least 12 consecutive months (TI12), according to data available as of August 20, 2026. (brlmed.com)

A total of 30 TDT patients have been treated in the pivotal study, and all 30 have achieved transfusion independence.

At the August 20 data cutoff, every treated patient remained transfusion-independent and no longer required red blood cell transfusions.

Not all 30 patients have yet completed the required 12 months of follow-up. However, enough patients have already reached TI12 for the trial to satisfy its prespecified primary efficacy criterion, according to BRL Medicine. (brlmed.com)

The result represents an important step toward a potential regulatory filing for BRL-101 in China and moves the homegrown gene-editing therapy closer to possible commercialization.

A One-Time Gene-Edited Treatment for β-Thalassemia

BRL-101 is an autologous CRISPR-Cas9 gene-edited hematopoietic stem and progenitor cell therapy.

The treatment starts with a patient’s own CD34+ hematopoietic stem and progenitor cells. These cells are collected and genetically edited outside the body before being returned to the patient following conditioning.

Rather than attempting to repair each patient’s individual β-globin mutation, BRL-101 edits an erythroid-specific regulatory region of BCL11A, a transcription factor that normally suppresses fetal hemoglobin after birth. (ichgcp.net)

Conceptually, the strategy works as follows:

Patient CD34+ stem cells → CRISPR-Cas9 editing of BCL11A regulatory region → increased fetal hemoglobin (HbF) → restoration of functional hemoglobin → elimination of chronic transfusion dependence

By reducing BCL11A activity specifically in the erythroid lineage, BRL-101 is designed to reactivate production of fetal hemoglobin (HbF).

The increased HbF can compensate for deficient or absent adult β-globin production in patients with β-thalassemia.

The ultimate objective is ambitious but straightforward: replace lifelong supportive transfusions with a single administration capable of producing durable transfusion independence.

All 30 Pivotal-Trial Patients Achieve Transfusion Independence

The latest results provide the strongest clinical validation of BRL-101 reported to date.

BRL Medicine said:

Pivotal BRL-101 Study	Result as of Aug. 20, 2026
Patients treated	30
Patients achieving transfusion independence	30/30 (100%)
Patients still transfusion-independent at cutoff	30/30 (100%)
Primary efficacy measure	TI12
Prespecified TI12 efficacy requirement	Met
Treatment approach	Single infusion of gene-edited autologous CD34+ cells

Importantly, 100% transfusion independence among the 30 patients should not be interpreted as a final 100% TI12 rate.

Some patients have not yet accumulated 12 months of follow-up. BRL Medicine instead reported that the number of patients who have already maintained transfusion independence for 12 months is sufficient for the pivotal study to meet its prespecified primary efficacy endpoint. (brlmed.com)

The company will continue following all patients to assess durability, hemoglobin levels, hematopoietic function and long-term safety.

Full statistical results are expected to be released once additional follow-up has matured.

From TI6 in July to Primary Endpoint Success in August

The milestone follows another important BRL-101 update just one month earlier.

On July 22, 2026, BRL Medicine reported that all 30 patients in the pivotal Phase 2 study had been dosed and had achieved at least six months of transfusion independence (TI6). BRL Medicine’s six-year BRL-101 follow-up announcement

At that point, the patients continued to be followed toward the more important TI12 endpoint.

Just over a month later, the trial has now crossed the prespecified threshold required for the primary efficacy endpoint.

The progression provides a clearer picture of the program:

30/30 achieved TI6 → 30/30 remain transfusion-independent → sufficient patients achieve TI12 → pivotal primary efficacy endpoint met

For a potentially one-time treatment for TDT, durability is particularly important. The therapeutic value of gene editing depends not simply on temporarily reducing transfusion requirements but on generating a stable population of genetically modified stem cells capable of continuously producing healthy blood cells.

Six-Year Follow-Up Provides Evidence of Durability

BRL-101 also has something relatively unusual for a Chinese gene-editing program: six years of human follow-up in its earliest patients.

The first pediatric patient with severe β⁰/β⁰ transfusion-dependent β-thalassemia received BRL-101 in July 2020.

Six years later, the child remains transfusion-independent.

BRL Medicine reported in July that the patient’s hemoglobin remained around 140 g/L, within the normal range, with normal growth, development and daily activities. (brlmed.com)

A second pediatric patient with the β⁰/β⁺ genotype, treated during the same period, has likewise remained transfusion-independent for approximately six years, with hemoglobin around 120 g/L and normal growth and development. (brlmed.com)

The combination of these long-term observations and the larger pivotal study is important.

Early BRL-101 research established proof of concept in a handful of patients. The pivotal study now begins to test whether those results can be reproduced systematically in a substantially larger population.

45 Patients Had Been Treated by Early 2026

BRL Medicine presented a broader clinical update at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.

As of the February 20, 2026 data cutoff, 45 thalassemia patients had received BRL-101 across the company’s clinical development program. (brlmed.com)

Among the 15 patients treated in earlier IIT and Phase 1 studies, all had maintained transfusion independence for at least 12 months, with a median follow-up of approximately 36.5 months and the longest follow-up approaching six years.

Meanwhile, all 30 participants in the pivotal Phase 2 study had already received BRL-101 and achieved at least TI6.

According to BRL Medicine’s July update, no graft-versus-host disease had been observed, and there had been no study withdrawals or deaths attributed to adverse events. (brlmed.com)

Longer-term safety surveillance remains essential, particularly for therapies involving permanent genome editing and myeloablative conditioning.

Why Transfusion Independence Matters

β-thalassemia is an inherited blood disorder caused by mutations that reduce or eliminate production of functional β-globin, an essential component of adult hemoglobin.

Patients with severe transfusion-dependent disease require regular red blood cell transfusions to maintain adequate hemoglobin.

Those transfusions keep patients alive but create their own long-term complications.

Repeated transfusions can lead to iron overload, which may progressively damage the liver, heart, endocrine organs and other tissues. Patients therefore frequently require lifelong iron-chelation therapy in addition to regular transfusions.

A therapy capable of restoring sufficient endogenous hemoglobin production could fundamentally change that disease burden.

For this reason, sustained transfusion independence has become a critical efficacy measure for potentially curative gene therapies in TDT.

BRL-101’s TI12 endpoint therefore asks a clinically meaningful question: can patients maintain adequate hemoglobin without requiring red blood cell transfusions for at least a full year?

The pivotal trial has now met that test at its prespecified efficacy threshold. (brlmed.com)

BRL-101 Joins a New Era of Gene-Edited Hemoglobinopathy Treatments

BRL-101 is entering a field transformed by gene therapy and genome editing.

The global validation of CRISPR-based treatments for hemoglobin disorders has established that editing a patient’s own hematopoietic stem cells can produce durable therapeutic benefits.

BRL-101 follows the broader fetal-hemoglobin-reactivation strategy but is being developed specifically as a domestically originated therapy for Chinese and potentially international markets.

Its development could be particularly relevant because China has a substantial thalassemia population, with the disease concentrated especially in southern regions.

BRL Medicine also emphasizes its use of a non-viral gene-editing process.

Because BRL-101 uses CRISPR-mediated editing rather than integrating a therapeutic gene through a viral vector, it avoids the insertional integration mechanism associated with conventional lentiviral gene-addition therapies. (brlmed.com)

That does not mean gene editing is risk-free. Off-target editing, clonal abnormalities, conditioning-related toxicities and other potential long-term risks require careful surveillance.

Long-term patient monitoring will therefore remain central to evaluating BRL-101’s overall benefit-risk profile.

Regulatory Filing Moves Into Focus

Meeting the pivotal study’s primary efficacy endpoint shifts attention toward BRL-101’s next major milestone: regulatory submission in China.

BRL Medicine said it will continue protocol-specified follow-up while completing the full statistical analysis and preparing for regulatory filing. (brlmed.com)

The company is also strengthening capabilities related to manufacturing, quality systems and industrialization as BRL-101 moves closer to potential commercialization.

Several milestones will now be particularly important:

final TI12 results across the full pivotal cohort;
detailed hemoglobin and fetal-hemoglobin data;
longer-term durability of transfusion independence;
complete safety results, including gene-editing and conditioning-related safety;
regulatory filing and acceptance by China’s NMPA; and
manufacturing and commercial readiness for an individualized autologous therapy.

The regulatory timeline has not yet been formally disclosed.

BRL Medicine Builds Broader Gene and Cell Therapy Pipeline

BRL-101 is the most advanced program within a broader gene and cell therapy portfolio at BRL Medicine.

The Shanghai-based company describes itself as a platform biotechnology company developing treatments across genetic diseases, autoimmune diseases, hematological malignancies and solid tumors.

Its technology portfolio includes hematopoietic stem cell gene editing, universal allogeneic immune-cell therapy and in vivo cell-therapy approaches. BRL Medicine company overview

Beyond BRL-101, the company has reported clinical development involving universal CAR-T and other engineered cell therapies, giving it one of the broader gene-editing-focused pipelines among China’s private biotechnology companies. (brlmed.com)

A Major Step Toward Potential Commercialization

The latest result represents an important transition for BRL-101.

The program has moved from treating the world’s first pediatric β⁰/β⁰ TDT patient in 2020, through early proof-of-concept and Phase 1 development, to a pivotal study in which all 30 treated patients have achieved transfusion independence.

More importantly from a regulatory perspective, the trial has now met its prespecified TI12 primary efficacy endpoint.

Six-year transfusion independence in the earliest patients adds an encouraging durability signal to the larger pivotal dataset.

The next test will be whether the complete dataset supports regulatory approval.

If it does, BRL-101 could become an important domestically developed gene-editing treatment for transfusion-dependent β-thalassemia and further establish China as a significant player in the development and commercialization of genome-edited medicines.

For now, however, BRL-101 remains investigational. Full pivotal results, longer follow-up and regulatory review will ultimately determine whether the therapy can translate its striking clinical results into an approved treatment.

References

Tags: